Cargando…

The Quest for an Alzheimer Therapy

This mini-review considers three different approaches to the therapy and prevention of Alzheimer’s disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on differ...

Descripción completa

Detalles Bibliográficos
Autor principal: Cappa, Stefano F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863504/
https://www.ncbi.nlm.nih.gov/pubmed/29599741
http://dx.doi.org/10.3389/fneur.2018.00108
_version_ 1783308404035420160
author Cappa, Stefano F.
author_facet Cappa, Stefano F.
author_sort Cappa, Stefano F.
collection PubMed
description This mini-review considers three different approaches to the therapy and prevention of Alzheimer’s disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry.
format Online
Article
Text
id pubmed-5863504
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58635042018-03-29 The Quest for an Alzheimer Therapy Cappa, Stefano F. Front Neurol Neuroscience This mini-review considers three different approaches to the therapy and prevention of Alzheimer’s disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry. Frontiers Media S.A. 2018-03-01 /pmc/articles/PMC5863504/ /pubmed/29599741 http://dx.doi.org/10.3389/fneur.2018.00108 Text en Copyright © 2018 Cappa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Cappa, Stefano F.
The Quest for an Alzheimer Therapy
title The Quest for an Alzheimer Therapy
title_full The Quest for an Alzheimer Therapy
title_fullStr The Quest for an Alzheimer Therapy
title_full_unstemmed The Quest for an Alzheimer Therapy
title_short The Quest for an Alzheimer Therapy
title_sort quest for an alzheimer therapy
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863504/
https://www.ncbi.nlm.nih.gov/pubmed/29599741
http://dx.doi.org/10.3389/fneur.2018.00108
work_keys_str_mv AT cappastefanof thequestforanalzheimertherapy
AT cappastefanof questforanalzheimertherapy